LCM
TRDA icon

Lynx1 Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Lynx1 Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
211,689
+160,000
+310% +$1.83M 0.42% 13
2025
Q4 		$531K Buy
+51,689
New +$436K 0.11% 17

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lynx1 Capital Management's TRDA Position: Q1 2026 in Review

Lynx1 Capital Management increased its Entrada Therapeutics (TRDA) stake by 310% in Q1 2026, buying an estimated $1.83M and bringing the position to 211,689 shares worth $2.67M. The position accounts for 0.42% of the portfolio, ranked #13.

Lynx1 Capital Management first reported a position in TRDA in Q4 2025 and has held it in 2 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Lynx1 Capital Management held 211,689 shares of Entrada Therapeutics worth $2.67M as of Q1 2026.
  • Lynx1 Capital Management bought 160,000 Entrada Therapeutics shares in Q1 2026, an estimated $1.83M.
  • Entrada Therapeutics made up 0.42% of Lynx1 Capital Management's portfolio in Q1 2026, its #13 holding.
  • Lynx1 Capital Management first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.